- The Tech 40 label recognizes particularly outstanding listed technology companies.
- Deinove is one of the 40 companies selected from among 330 eligible European stocks.
- This distinction will increase the company's recognition and visibility in financial markets.
MONTPELLIER, France, April 21, 2016 (GLOBE NEWSWIRE) -- DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria, announced today that it had been selected from among 330 listed European high technology securities to join the Tech 40 Label and the corresponding stock market index, EnterNext Tech 40.
The "Tech 40" label, an initiative launched by EnterNext, brings together emblematic companies in the Tech sector listed on the Euronext markets (Amsterdam, Brussels, Lisbon and Paris) and working in life sciences, eco-industries and TMT. The 40 companies receiving the label in 2016 were chosen by a group of independent European experts on the basis of economic, financial and stockmarket performance.
With this label, Deinove will enjoy one year of promotion and special assistance aimed at raising its visibility in the market, notably through a roadshow program targeting European and international investors.
"We are proud to be included in the European Tech 40 label, which groups together companies that are references in their fields and have strong potential in the technology sector," said Emmanuel Petiot, CEO of Deinove. "This label, which promotes the innovative nature of our activity, will also enable us to increase our visibility among international investors."
Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalizations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs.
EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level.
DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com
| DEINOVE |
Tel.: +33 (0)4 48 19 01 28
Communication and Investor relations
Tel.: +33 (0)4 48 19 01 60
| ALIZE RP, Press Relations |
Caroline Carmagnol / Wendy Rigal
Tel.: +33 (0)1 44 54 36 66
PR in English http://hugin.info/142979/R/2005667/740880.pdf